126 related articles for article (PubMed ID: 15183956)
1. Expression of cathepsins B, H, and L and their inhibitors as markers of transitional cell carcinoma of the bladder.
Staack A; Tolic D; Kristiansen G; Schnorr D; Loening SA; Jung K
Urology; 2004 Jun; 63(6):1089-94. PubMed ID: 15183956
[TBL] [Abstract][Full Text] [Related]
2. Cathepsins B, H, and L activities in urine of patients with transitional cell carcinoma of the bladder.
Staack A; Koenig F; Daniltchenko D; Hauptmann S; Loening SA; Schnorr D; Jung K
Urology; 2002 Feb; 59(2):308-12. PubMed ID: 11834417
[TBL] [Abstract][Full Text] [Related]
3. Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue.
Friedrich B; Jung K; Lein M; Türk I; Rudolph B; Hampel G; Schnorr D; Loening SA
Eur J Cancer; 1999 Jan; 35(1):138-44. PubMed ID: 10211102
[TBL] [Abstract][Full Text] [Related]
4. Cathepsin expression in oral squamous cell carcinoma: relationship with clinicopathologic factors.
Kawasaki G; Kato Y; Mizuno A
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 Apr; 93(4):446-54. PubMed ID: 12029284
[TBL] [Abstract][Full Text] [Related]
5. Matrigel influences morphology and cathepsin B distribution of prostate cancer PC3 cells.
Gopal P; Rehman RU; Chadha KS; Qiu M; Colella R
Oncol Rep; 2006 Aug; 16(2):313-20. PubMed ID: 16820909
[TBL] [Abstract][Full Text] [Related]
6. Assessment of cathepsin L activity by use of the inhibitor CA-074 compared to cathepsin B activity in human lung tumor tissue.
Werle B; Ebert W; Klein W; Spiess E
Biol Chem Hoppe Seyler; 1995 Mar; 376(3):157-64. PubMed ID: 7612192
[TBL] [Abstract][Full Text] [Related]
7. Cathepsins B and L are markers for clinically invasive types of meningiomas.
Strojnik T; Zidanik B; Kos J; Lah TT
Neurosurgery; 2001 Mar; 48(3):598-605. PubMed ID: 11270551
[TBL] [Abstract][Full Text] [Related]
8. An activity-based probe for the determination of cysteine cathepsin protease activities in whole cells.
Falgueyret JP; Black WC; Cromlish W; Desmarais S; Lamontagne S; Mellon C; Riendeau D; Rodan S; Tawa P; Wesolowski G; Bass KE; Venkatraman S; Percival MD
Anal Biochem; 2004 Dec; 335(2):218-27. PubMed ID: 15556560
[TBL] [Abstract][Full Text] [Related]
9. Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma.
Svatek RS; Karam J; Karakiewicz PI; Gallina A; Casella R; Roehrborn CG; Shariat SF
J Urol; 2008 Feb; 179(2):478-84; discussion 484. PubMed ID: 18076936
[TBL] [Abstract][Full Text] [Related]
10. Identification and discrimination of extracellularly active cathepsins B and L in high-invasive melanoma cells.
Klose A; Zigrino P; Dennhöfer R; Mauch C; Hunzelmann N
Anal Biochem; 2006 Jun; 353(1):57-62. PubMed ID: 16620747
[TBL] [Abstract][Full Text] [Related]
11. Determination of cathepsins B, H, L and kininogen in breast cancer patients.
Gabrijelcic D; Svetic B; Spaić D; Skrk J; Budihna J; Turk V
Agents Actions Suppl; 1992; 38 ( Pt 2)():350-7. PubMed ID: 1334335
[TBL] [Abstract][Full Text] [Related]
12. Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators.
Lah TT; Cercek M; Blejec A; Kos J; Gorodetsky E; Somers R; Daskal I
Clin Cancer Res; 2000 Feb; 6(2):578-84. PubMed ID: 10690542
[TBL] [Abstract][Full Text] [Related]
13. Cathepsins B, H and L in human breast carcinoma.
Gabrijelcic D; Svetic B; Spaić D; Skrk J; Budihna M; Dolenc I; Popovic T; Cotic V; Turk V
Eur J Clin Chem Clin Biochem; 1992 Feb; 30(2):69-74. PubMed ID: 1316176
[TBL] [Abstract][Full Text] [Related]
14. Cells producing cathepsins D, B, and L in human breast carcinoma and their association with prognosis.
Lah TT; Kalman E; Najjar D; Gorodetsky E; Brennan P; Somers R; Daskal I
Hum Pathol; 2000 Feb; 31(2):149-60. PubMed ID: 10685628
[TBL] [Abstract][Full Text] [Related]
15. Regulation of cathepsin B and L expression in vitro in gastric cancer tissues by egg cystatin.
Saleh Y; Siewiński M; Kielan W; Ziółkowski P; Gryboś M; Rybka J
J Exp Ther Oncol; 2003; 3(6):319-24. PubMed ID: 14678520
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic significance of cathepsin B immunostaining in transitional neoplasia.
Visscher DW; Sloane BF; Sameni M; Babiarz JW; Jacobson J; Crissman JD
Mod Pathol; 1994 Jan; 7(1):76-81. PubMed ID: 8159656
[TBL] [Abstract][Full Text] [Related]
17. Marked increases in cathepsin B and L activities distinguish papillary carcinoma of the thyroid from normal thyroid or thyroid with non-neoplastic disease.
Shuja S; Murnane MJ
Int J Cancer; 1996 May; 66(4):420-6. PubMed ID: 8635854
[TBL] [Abstract][Full Text] [Related]
18. Cysteine proteases and cysteine protease inhibitors in non-small cell lung cancer.
Krepela E; Procházka J; Kárová B; Cermák J; Roubková H
Neoplasma; 1998; 45(5):318-31. PubMed ID: 9921922
[TBL] [Abstract][Full Text] [Related]
19. High expression of cathepsin B in transitional bladder carcinoma correlates with tumor invasion.
Eiján AM; Sandes EO; Riveros MD; Thompson S; Pasik L; Mallagrino H; Celeste F; Casabé AR
Cancer; 2003 Jul; 98(2):262-8. PubMed ID: 12872343
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of human bladder tumor invasion: role of protease cathepsin B.
Weiss RE; Liu BC; Ahlering T; Dubeau L; Droller MJ
J Urol; 1990 Sep; 144(3):798-804. PubMed ID: 2201799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
